Hinge Health Inc. Class A Common Stock vs Honeywell Aerospace Inc. Common Stock — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Honeywell Aerospace Inc. Common Stock trades at $156.54 (market cap $50.14B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 5.9× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Honeywell Aerospace Inc. Common Stock for 0 Days on average.
| HNGE | HONA | |
|---|---|---|
Market Cap | $8.48B | $50.14B |
Volume | 879,799 | 1,433,364 |
Sector | Health | Industrials |
52-Week High | $105.14 | $269.95 |
52-Week Low | $31.17 | $151.58 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $8.10B | $64.96B |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →